Edition:
United States

Titan Pharmaceuticals Inc (TTNP.OQ)

TTNP.OQ on NASDAQ Stock Exchange Capital Market

0.93USD
20 Jul 2018
Change (% chg)

$0.05 (+5.65%)
Prev Close
$0.88
Open
$0.91
Day's High
$0.95
Day's Low
$0.91
Volume
2,732
Avg. Vol
16,448
52-wk High
$2.80
52-wk Low
$0.60

Chart for

About

Titan Pharmaceuticals, Inc. (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. The Company's segment is engaged in the development of pharmaceutical products. The Company's product development programs utilize its long-term drug delivery... (more)

Overall

Beta: 1.25
Market Cap(Mil.): $18.67
Shares Outstanding(Mil.): 21.20
Dividend: --
Yield (%): --

Financials

  TTNP.OQ Industry Sector
P/E (TTM): -- 29.12 33.34
EPS (TTM): -0.66 -- --
ROI: -207.94 13.60 13.18
ROE: -284.95 15.30 15.09

BRIEF-Titan Pharmaceuticals Q1 Loss Per Share $0.12

* TITAN PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

May 15 2018

BRIEF-Titan Pharmaceuticals: Names Federico Seghi Recli To Board

* ACCOMPLISHED GLOBAL PHARMACEUTICAL EXECUTIVE, FEDERICO SEGHI RECLI, APPOINTED TO TITAN'S BOARD Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

May 14 2018

BRIEF-Titan Pharmaceuticals Q4 Loss Per Share $0.17

* TITAN PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Apr 02 2018

BRIEF-Titan Pharmaceuticals Executes Agreement For Acquisition By Molteni Of Probuphine In Europe And Other Territories

* TITAN EXECUTES AGREEMENT FOR ACQUISITION BY MOLTENI OF PROBUPHINE® IN EUROPE AND OTHER SELECT TERRITORIES

Mar 21 2018

BRIEF-Titan Announces Amendment To Horizon Loan Agreement

* TITAN PHARMACEUTICALS INC - ENTRY INTO AN AMENDMENT TO JULY 2017 LOAN AGREEMENT WITH HORIZON TECHNOLOGY FINANCE CORPORATION

Feb 02 2018

Earnings vs. Estimates